Phase 4 Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are admitted for delivery, or enrolled in a postpartum blood pressure monitoring program following delivery, at the University of Michigan Labor and Delivery unit
- People who are at least 23 weeks pregnant at the time of delivery (single or multiple babies, with or without fetal anomalies)
- People who are able to read, speak, and understand English and are willing to sign a written consent form in English
- People who have been diagnosed with a high blood pressure condition during pregnancy — this includes those already taking blood pressure medication for chronic high blood pressure, those with a diagnosis of chronic or essential hypertension in their medical record, or those diagnosed with a pregnancy-related high blood pressure disorder (such as gestational hypertension, preeclampsia, or eclampsia) before delivery
- People who are able to name a planned method of contraception as part of the consent process
- People who have had two or more blood pressure readings of 160/110 mmHg or higher, at least 60 minutes apart — or, if that blood pressure level has not been reached, people who have a specific heart-stress marker (called BNP) measured at 100 or above within 12 hours of delivery (confirm with trial site)
Who may not be able to join:
- People who do not speak English
- People who are still pregnant at the time of enrollment
- People who plan to become pregnant within 8 months of delivery
- People who intend to breastfeed after enrolling in the trial
- People whose BNP heart-stress marker measures 1,000 or above within 12 hours of delivery
- People with certain other health conditions that may affect assessment of heart and blood vessel risk (confirm with trial site for specifics)
- People for whom the study drug, dapagliflozin, would not be medically appropriate (confirm with trial site for specifics)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ashley Hesson, MD, PhD, University of Michigan
Phone: 734-763-0295
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Cardiovascular risk reduction score
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.